Sirna Q2 Losses Rise as Company Spends Ahead Of HCV Phase I Trial; Officials Give Study Details - RNAi

Sirna Q2 Losses Rise as Company Spends Ahead Of HCV Phase I Trial; Officials Give Study Details

Sirna Q2 Losses Rise as Company Spends Ahead Of HCV Phase I Trial; Officials Give Study Details
By Doug Macron
August 17, 2006
RNAi News
The majority of the company?s second-quarter expenses were tied to pre-IND research on its HCV drug candidate, Sirna-034, as well as the manufacture of the drug for an upcoming phase I study.
Paid subscription is required to view article.